| | |
C.H.Unnikrishnan 10:17 PM | April 13,2009
Depressed stock prices are one of the reasons behind foreign firms’ plans to raise stakes in their Indian subsidiaries
|
|
C.H.Unnikrishnan 12:13 AM | October 23,2008
A finance cost of Rs40.8 crore, clubbed with a voluntary retirement scheme offered to employees that cost Rs9 crore, caused the fall in profit
|
|
C.H.Unnikrishnan 10:51 PM | July 25,2008
The first equity participation of its kind in the Indian wine sector will ensure Four Seasons a regular supply of wine-grade grapes, replacing the existing contract-farming model
|
|
C.H.Unnikrishnan and P.R. Sanjai 01:08 AM | May 22,2008
Improved ambience and rich product range at new airports now draw Indian consumers
|
|
C.H.Unnikrishnan 12:01 AM | December 12,2007
The drug, whose generic name is Maraviroc, was granted a patent in India by the Mumbai patent office in June
|
|
C.H.Unnikrishnan 11:14 PM | November 26,2007
The company is currently equipped to handle services such as informatics, chemical synthesis, discovery, clinical trials
|
|
C.H.Unnikrishnan 01:38 AM | November 26,2007
Compulsory declaration of the source of origin of any data related to natural resources will check exploitation
|
|
C.H.Unnikrishnan 12:48 AM | November 21,2007
Iressa is the third non-Indian drug brand to be turned down under relatively new Indian patent laws
|
|
C.H.Unnikrishnan 12:36 AM | October 10,2007
It will manufacture and sell so-called nuclear medicines used in patients for advanced diagnostics
|
|
C.H.Unnikrishnan, Tarun Shukla and P.R. Sanjai 12:28 AM | September 03,2007
However, Vijay Mallya claimed his airline will anyway become eligible to operate international flights next year
|
|
Bhuma Shrivastava and C.H.Unnikrishnan 12:52 AM | August 01,2007
The Drug Controller General of India will do its own pharmacovigilance inquiry into the health effects of the drug
|
|
C.H.Unnikrishnan 01:24 AM | June 23,2007
The new treatment for drug-resistant bacterial infection from Wyeth will cost a patient around Rs6,000 a day
|
|
By C.H.Unnikrishnan 06:07 AM | June 18,2007
The company’s policy is to stay away from the ongoing ‘mad rush’ for acquisitions unless it makes strategic sense
|
|
Bhuma Shrivastava and C.H.Unnikrishnan 12:31 AM | April 14,2007
The demand is “not tenable” and contrary to the orders of the Supreme Court, the Mumbai-based company said in a regulatory filing with the Bombay Stock Exchange (BSE)
|
|
Bhuma Shrivastava and C.H.Unnikrishnan 02:27 AM | March 01,2007
The pharmaceutical industry gets a tax break up to March 2012 allowing firms to set off 1.5 times the money they spend on research and development
|
|